Cimzia kit is a prescription medicine containing Certolizumab pegol, marketed by UCB, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Refrigerate CIMZIA vials and prefilled syringes between 2°C to 8°C (36°F to…
Key facts
- Active ingredient (INN)
- Certolizumab pegol
- Brand
- Cimzia
- Dosage form
- Kit
- Packs
- 2 kits
- Marketing authorisation holder
- UCB
- Manufacturer
- UCB
- Origin register
- US FDA, United States
- Storage
- Refrigerate CIMZIA vials and prefilled syringes between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Unopened CIMZIA lyophilized vials may also be stored at room temperature up to a maximum of 25°C (77°F) for 6 months, but not exceeding the original expiration date.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AB05 Certolizumab pegol
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 April 2008
- Identifiers
- RxCUI 795081, 795085, 849597 +5DailyMed set ID b4c2c9dc-a0bb-4d64-a667-a67ebe88392dNDC 50474-700Application BLA125160
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 kit in 1 carton / 1 kit in 1 kit * 1 mL in 1 vial, glass * 1 mL in 1 vial, glass | 50474-700-62 | UCB | 20 April 2008 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Certolizumab pegol
Clinical summary
Certolizumab pegol is a tumor necrosis factor blocker indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease, among other approved uses. MedsAcross supplies Certolizumab pegol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Certolizumab pegolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cimzia prescribing information (UCB) · U.S. National Library of Medicine, DailyMed
- Cimzia: European public assessment report (EPAR) · European Medicines Agency
Need Cimzia kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.